首页|特应性皮炎治疗药物的研究进展

特应性皮炎治疗药物的研究进展

扫码查看
特应性皮炎(AD)是一种慢性、复发性、炎症性皮肤病,常伴有其他特应性表现,可同时对儿童及成人造成影响.多项研究表明,AD患者的疾病负担较重,对公共卫生有重要影响.目前国内外大量研究表明,AD的发病机制涉及皮肤免疫炎症、皮肤屏障和皮肤菌群,提出表皮通透屏障功能受损是AD发病机制中的重要环节.因此,修复和保护皮肤屏障功能,维持皮肤微生态平衡对AD的治疗尤为重要.AD的治疗涉及基础治疗、外用药物治疗、物理治疗和系统药物治疗等多个方面.对于轻至中度患者而言,在基础治疗的基础上,可以采用外用药物和口服抗组胺药等进行治疗.而对于中重度患者,则可以选择系统治疗.其中,一些创新疗法以生物制剂为代表,取得了重要的进展,能够有效抑制2型炎症,有助于患者实现长期的病情控制.同时天然药物的挖掘和开发也越来越受到关注,将为AD患者的治疗提供更多选择.
Research progress of drugs for the treatment of atopic dermatitis
Atopic dermatitis(AD)is a chronic,relapsing,inflammatory dermatosis.It is an inflammatory chronic dermatosis,often associated with other atopic manifestations,that can affect both children and adults.Multiple studies have shown that people with AD have a higher burden of disease,with important implications for public health.At present,a large number of studies at home and abroad have shown that the pathogenesis of AD involves skin immune inflammation,skin barrier and skin flora,proposing that the impaired epidermal permeability barrier function is an important link in the pathogenesis of AD,therefore,repairing and protecting the skin barrier function,and maintaining the skin microecological balance are particularly important for the treatment of AD.The treatment of AD involves a number of aspects such as basic treatment,topical medication,physiotherapy and systemic medication.For mild to moderate patients,on the basis of basic treatment,topical medications and oral antihistamines can be used.For moderate to severe patients,systemic therapy is an option.Some innovative therapies represented by biologic have made important progress,which can effectively inhibit type 2 inflammation and help patients achieve long-term disease control.Meanwhile,the mining and development of natural medicines is also receiving increasing attention and will provide more options for the treatment of AD patients.

Atopic dermatitisType 2 inflammationSkin barrierSkin floraBiological agentsNatural medicines

邹瑞、李娟、李劲松

展开 >

湖北省药品监督检验研究院生物安全中心(武汉 430075)

湖北中医药大学药学院(武汉 430061)

特应性皮炎 2型炎症 皮肤屏障 皮肤菌群 生物制剂 天然药物

湖北中药质控标准物质研制及技术平台项目

2020ACA007

2024

药物流行病学杂志
中国药学会 武汉医药(集团)股份有限公司

药物流行病学杂志

CSTPCD
影响因子:0.746
ISSN:1005-0698
年,卷(期):2024.33(4)
  • 4